Skip to content



Pfizer has opened the call for interested U.S. startup companies to submit non-confidential proposals for a Pfizer-sponsored LabCentral Golden Ticket*

Pfizer recognizes that new ideas are essential to scientific progress, and the events of the past year have only strengthened our deep-seated belief that Science Will Win. By providing LabCentral residencies through the Golden Ticket program, Pfizer aims to support the entrepreneurial, early stage activities of startup companies that are pursuing innovative research – to advance the leading edge of science and facilitate breakthroughs that positively impact human health.

LabCentral is a network of shared laboratory spaces located in the heart of Cambridge, MA, proximate to Pfizer’s campus in Kendall Square, and designed as a launchpad for high-potential life sciences and biotech startups. As a LabCentral platinum sponsor, Pfizer can select up to two startup companies each year to take up residence in LabCentral’s Kendall Square facility at 700 Main Street. The Golden Ticket will provide a selected startup with one year of bench space for one scientist, including the benefits of shared infrastructure and services.

High-potential life sciences and biotech startup applicants will be considered. Interested companies meeting the program eligibility requirements can submit an application for consideration by May 17, 2021.

  • Hosted By


  • Date

    May 17, 2021